{"id":30803,"date":"2026-07-16T04:09:00","date_gmt":"2026-07-15T20:09:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=30803"},"modified":"2026-07-16T05:54:24","modified_gmt":"2026-07-15T21:54:24","slug":"nejm%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e9%ab%98%e5%8d%b1%e9%97%a8%e8%af%8a%e6%82%a3%e8%80%85%e5%8f%a3%e6%9c%8d%e5%a5%88%e7%8e%9b%e7%89%b9%e9%9f%a6-%e5%88%a9%e6%89%98%e9%82%a3%e9%9f%a6","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=30803","title":{"rendered":"[NEJM\u53d1\u8868\u8bba\u6587]\uff1a\u9ad8\u5371\u95e8\u8bca\u60a3\u8005\u53e3\u670d\u5948\u739b\u7279\u97e6-\u5229\u6258\u90a3\u97e6\u6cbb\u7597\u65b0\u51a0\u80ba\u708e"},"content":{"rendered":"\n

ORIGINAL ARTICLE<\/a><\/p>\n\n\n\n

Oral Nirmatrelvir\u2013Ritonavir for Covid-19 in Higher-Risk Outpatients<\/h1>\n\n\n\n

Christopher C.\u00a0Butler,\u00a0Andrew D.\u00a0Pinto,\u00a0Victoria\u00a0Harris,\u00a0et al<\/h3>\n\n\n\n

N Engl J Med\u00a02026;394:1583-1594<\/h3>\n\n\n\n

DOI: 10.1056\/NEJMoa2502457<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

BACKGROUND<\/h3>\n\n\n\n

Nirmatrelvir\u2013ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir\u2013ritonavir in persons who have been vaccinated, infected naturally, or both is unclear.<\/p>\n\n\n\n

METHODS<\/h3>\n\n\n\n

In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (\u226550 years of age or \u226518 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 days or less. The participants were randomly assigned to receive usual care plus nirmatrelvir (300 mg)\u2013ritonavir (100 mg) twice a day for 5 days or to receive usual care alone. The primary outcome was hospitalization or death from any cause within 28 days after randomization.<\/p>\n\n\n\n

RESULTS<\/h3>\n\n\n\n

From December 8, 2021, to September 30, 2024, a total of 3516 participants in the PANORAMIC trial and 716 participants in the CanTreatCOVID trial underwent randomization. In the PANORAMIC trial, 14 of 1698 participants (0.8%) in the nirmatrelvir\u2013ritonavir group and 11 of 1673 participants (0.7%) in the usual-care group were hospitalized or died (adjusted odds ratio, 1.18; 95% Bayesian credible interval, 0.55 to 2.62; probability of superiority, 0.334). In the CanTreatCOVID trial, 2 of 343 participants (0.6%) in the nirmatrelvir\u2013ritonavir group and 4 of 324 participants (1.2%) in the usual-care group were hospitalized or died (adjusted odds ratio, 0.48; 95% Bayesian credible interval, 0.08 to 2.23; probability of superiority, 0.830). In a substudy involving 634 participants, viral load was reduced by the end of treatment with nirmatrelvir\u2013ritonavir. Serious adverse events with nirmatrelvir\u2013ritonavir were reported in 9 participants in the PANORAMIC trial and in 4 participants in the CanTreatCOVID trial.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n

CONCLUSIONS<\/h3>\n\n\n\n

In two open-label trials, nirmatrelvir\u2013ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. (Funded by the National Institute for Health and Care Research, and others; PANORAMIC ISRCTN number, 2021-005748-31<\/a>; CanTreatCOVID ClinicalTrials.gov number, NCT05614349<\/a>.)<\/p>\n","protected":false},"excerpt":{"rendered":"

ORIGINAL ARTICLE Oral Nirmatrelvir\u2013Ritonavir for Covid- […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30803"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30803"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30803\/revisions"}],"predecessor-version":[{"id":30808,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/30803\/revisions\/30808"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}